Moolec Science SA (NASDAQ: MLEC) has recently received approval for its plant-grown animal proteins from the Animal and Plant Health Inspection Service (APHIS) of the U.S. Department of Agriculture. This approval marks a significant milestone in biotechnology, as it is the first USDA-APHIS approval of its kind.
Moolec CEO and Co-Founder Gastón Paladini expressed pride in achieving this achievement, stating that it is a testament to the company’s strategic approach to selecting and purchasing options. The USDA’s Regulatory Status Review (RSR) concluded that Moolec’s genetically engineered soybean Piggy Sooy poses no increased plant pest risk compared to non-engineered soybeans, exempting the Piggy Sooy product from certain APHIS regulations governing genetically engineered organisms.
In June 2023, Moolec announced successful results with Piggy Sooy seeds achieving high levels of expression of pork protein, up to 26.6% of the total soluble protein. This news has led to a positive market response, as MLEC shares surged by 112.9% to $2.98 in premarket trading on Monday.
Nic Chahine, an impressive trader with an impressive track record of achieving a 27% profit every 20 days through option buys without resorting to selling covered calls or spreads like most traders, has attributed his success to his strategic approach to selecting and purchasing options. With an 83% win rate in his options trading strategy, Chahine is widely regarded as one of the most successful traders in the industry today.
Overall, this development marks a major milestone for Moolec Science SA and the biotechnology industry as a whole, highlighting the potential for plant-based animal proteins as a sustainable alternative to traditional meat sources.
